Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 16:8:697.
doi: 10.3389/fimmu.2017.00697. eCollection 2017.

Modulatory Effects of Antibody Replacement Therapy to Innate and Adaptive Immune Cells

Isabella Quinti  1 , Milica Mitrevski  2
Affiliations

Modulatory Effects of Antibody Replacement Therapy to Innate and Adaptive Immune Cells

Isabella Quinti et al. Front Immunol. .

Abstract

Intravenous immunoglobulin administered at replacement dosages modulates innate and adaptive immune cells in primary antibody deficiencies (PAD) in a different manner to what observed when high dosages are used or when their effect is analyzed by in vitro experimental conditions. The effects seem to be beneficial on innate cells in that dendritic cells maturate, pro-inflammatory monocytes decrease, and neutrophil function is preserved. The effects are less clear on adaptive immune cells. IVIg induced a transient increase of Treg and a long-term increase of CD4 cells. More complex and less understood is the interplay of IVIg with defective B cells of PAD patients. The paucity of data underlies the need of more studies on patients with PAD before drawing conclusions on the in vivo mechanisms of action of IVIg based on in vitro investigations.

Keywords: IVIg replacement; X-linked agammaglobulinemia; adaptive immunity; common variable immune disorders; in vivo; innate immunity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanisms of action of intravenous immunoglobulin (IVIg) on innate (neutrophils, monocytes, and dendritic cells) and adaptive (B and T lymphocytes) immune cells. Effects of IVIg (replacement dosages) (A); effects of IVIg (high dosages) (B). Cell images from Ref. (55).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Farrugia A, Quinti I. Manufacture of immunoglobulin products for patients with primary antibody deficiencies – the effect of processing conditions on product safety and efficacy. Front Immunol (2014) 5:665.10.3389/fimmu.2014.00665 - DOI - PMC - PubMed
    1. Kerr J, Quinti I, Eibl M, Chapel H, Späth PJ, Sewell WA, et al. Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Front Immunol (2014) 5:629.10.3389/fimmu.2014.00629 - DOI - PMC - PubMed
    1. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol (2011) 164(Suppl 2):2–5.10.1111/j.1365-2249.2011.04387.x - DOI - PMC - PubMed
    1. Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, et al. Intravenous immunoglobulins – understanding properties and mechanisms. Clin Exp Immunol (2009) 158(Suppl 1):2–13.10.1111/j.1365-2249.2009.04022.x - DOI - PMC - PubMed
    1. Nagelkerke SQ, Kuijpers TW. Immunomodulation by IVIg and the role of Fc gamma receptors: classic mechanisms of action after all? Front Immunol (2015) 5:674.10.3389/fimmu.2014.00674 - DOI - PMC - PubMed